Video Vault

Orphan Drugs

According to the company, the figure equals the number GPCRs targeted by more than 30 percent of currently marketed drugs.

Omeros Corp. today announced that it has identified compounds that functionally interact with each of four additional orphan G protein-coupled receptors (GPCRs). Without compounds that functionally interact with orphan GPCRs, developing drugs targeting those receptors is extremely difficult. Omeros has now unlocked 46 Class A orphan GPCRs, representing almost 60 percent of these targets and equaling the number of GPCRs that are targeted by over 30 percent of all marketed drugs.